Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyra Therapeutics (LYRA) Non-Current Deffered Revenue (2021 - 2025)

Lyra Therapeutics (LYRA) has disclosed Non-Current Deffered Revenue for 5 consecutive years, with $11.9 million as the latest value for Q3 2025.

  • On a quarterly basis, Non-Current Deffered Revenue changed 0.0% to $11.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was $11.9 million, a 0.0% change, with the full-year FY2024 number at $11.9 million, down 2.26% from a year prior.
  • Non-Current Deffered Revenue was $11.9 million for Q3 2025 at Lyra Therapeutics, roughly flat from $11.9 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $14.1 million in Q4 2022 to a low of $1.9 million in Q4 2021.
  • A 5-year average of $10.6 million and a median of $11.9 million in 2024 define the central range for Non-Current Deffered Revenue.
  • Peak YoY movement for Non-Current Deffered Revenue: soared 630.89% in 2022, then decreased 13.79% in 2023.
  • Lyra Therapeutics' Non-Current Deffered Revenue stood at $1.9 million in 2021, then skyrocketed by 630.89% to $14.1 million in 2022, then dropped by 13.79% to $12.1 million in 2023, then fell by 2.26% to $11.9 million in 2024, then changed by 0.0% to $11.9 million in 2025.
  • Per Business Quant, the three most recent readings for LYRA's Non-Current Deffered Revenue are $11.9 million (Q3 2025), $11.9 million (Q2 2025), and $11.9 million (Q1 2025).